EMA: List of centrally authorised products requiring a notification of a change for update of annexes

August 3, 2022

European Flag stars over a wavy blue background.

August 2022

EMA Regulatory and Procedural Guideline

Parallel distributors are only required to inform the EMA of changes to the labelling or leaflet related to any update of the annexes of marketing authorisation once a year in their annual update application, except in cases related to safety or quality issues. The downloadable table lists the centrally authorised products for which the EMA requires notifications of safety update before implementation.

Download List of Products

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs

TAGS: EMA Europe Agency Alerts Regulatory Sciences

Related Articles

EMA

August 19, 2022

EMA’s Emergency Task Force advises on intradermal use of Imvanex / Jynneos against monkeypox

August 19, 2022 EMA’s Emergency Task Force (ETF) has reviewed data on the monkeypox vaccine Imvanex 1 used as an intradermal injection (given just below the top layer of the skin). The vaccine is...

Continue reading the blog post
Computer generated image of COVID-19
EMA

June 15, 2022

EMA adopts first list of critical medicines for COVID-19

News On 7 June 2022, EMA's Medicines Shortages Steering Group (MSSG) adopted the list of critical medicines for the COVID-19 public health emergency. The medicines included in the list are authorised...

Continue reading the blog post
EMA flags in front of buildings.
EMA

June 23, 2022

EMA Checklist for annual updates for parallel distribution - Draft Guidance

22/06/2022 EMA/405782/2020 Rev. 3 Human Medicines Division The European Medicines Agency (hereinafter 'the Agency') asks its applicants to use this checklist in advance of submission of an annual...

Continue reading the blog post